Effects of Add-On Therapy with NDC-052, an Extract from Magnoliae Flos, in Adult Asthmatic Patients Receiving Inhaled Corticosteroids.
10.3904/kjim.2012.27.1.84
- Author:
Chan Sun PARK
1
;
Tae Bum KIM
;
Jae Young LEE
;
Jae Yong PARK
;
Yong Chul LEE
;
Seong Su JEONG
;
Yang Deok LEE
;
You Sook CHO
;
Hee Bom MOON
Author Information
1. Department of Internal Medicine, Heaundae Paik Hospital, Inje University, Busan, Korea.
- Publication Type:Original Article ; Clinical Trial ; Multicenter Study ; Research Support, Non-U.S. Gov't
- Keywords:
Asthma;
Drugs;
Chinese herbal;
Magnolin;
Magnoliae
- MeSH:
Administration, Inhalation;
Adrenal Cortex Hormones/*administration & dosage;
Adrenergic beta-2 Receptor Agonists/therapeutic use;
Adult;
Anti-Asthmatic Agents/administration & dosage/*therapeutic use;
Asthma/diagnosis/*drug therapy/physiopathology;
Drug Therapy, Combination;
Drugs, Chinese Herbal/*therapeutic use;
Female;
Forced Expiratory Volume;
Humans;
Lung/drug effects/physiopathology;
*Magnolia;
Male;
Middle Aged;
Peak Expiratory Flow Rate;
Prospective Studies;
Republic of Korea;
Severity of Illness Index;
Time Factors;
Treatment Outcome
- From:The Korean Journal of Internal Medicine
2012;27(1):84-90
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND/AIMS: There is a need for new anti-asthmatic medications with fewer side effects. NDC-052, an extract of the medicinal herb Magnoliae flos, which has a long history of clinical use, was recently found to have anti-inflammatory effects. Herein, we evaluated the effects of NDC-052 as an add-on therapy in patients with mild to moderate asthma using inhaled corticosteroids (ICS). METHODS: In a non-comparative, multi-center trial, 148 patients taking ICS received NDC-052 for eight weeks. We evaluated their forced expiratory volume in one second (FEV1), morning and evening peak expiratory flow rate (AM and PM PEFR), AM/PM asthma symptom scores, visual analogue symptom (VAS) scores, night-time wakening, frequency of short-acting beta2-agonist usage, and adverse events. RESULTS: After eight weeks, both AM and PM PEFRs were significantly improved. Asthma symptom scores, VAS scores, the frequency of nights without awakening, and the frequency of beta2-agonist use were also reduced. Most of the adverse drug reactions were mild and resolved spontaneously. CONCLUSIONS: The addition of NDC-052 to ICS had a beneficial effect on asthma control in patients with mild to moderate asthma, with good tolerability and fewer side effects. Further studies are necessary to evaluate the effects of NDC-052 in patients with severe and/or refractory asthma.
